Brief: AcuCort Signs Its First Commercial Agreement For Zeqmelit
Nov 23 (Reuters) - AcuCort AB ACUC.TE :
* ACUCORT SIGNS ITS FIRST COMMERCIAL AGREEMENT FOR THE
COMPANY'S
DRUG ZEQMELIT™
* ACUCORT AB - KAMADA'S ASSESSMENT IS THAT CO WILL BE ABLE
TO
APPLY FOR REGISTRATION AND MARKET APPROVAL TO ISRAELI AUTHORITY
MOH IN Q1 OF 2023
* ACUCORT AB - AGREEMENT GIVES KAMADA EXCLUSIVE RIGHT TO
MARKETING
AND SALES AS WELL AS DISTRIBUTION OF ZEQMELIT IN ISRAELI MARKET
Source text for Eikon: ID:nPreFRXYPa
Further company coverage: ACUC.TE
((Reuters.Briefs@thomsonreuters.com;))
Recent news on AcuCort AB
See all newsBrief: Acucort Plans To Apply For U.S. Market Approval For Zeqmelit In 2026
Brief: AcuCort Signs Its First Commercial Agreement For Zeqmelit
Brief: Acucort AB Acucort Receives Marketing Authorization For Drug Zeqmelit By Norwegian Medicines Agency
Brief: Acucort Receives Marketing Authorization For The Drug Zeqmelit By The Danish Medicines Agency
Brief: AcuCort Is Granted Sme Status By The European Medicines Agency, EMA